Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Both men and women are affected equally but the most common age groups are children and young adults
REDEFINE-1: Phase 3 Pivotal Trial (NCT05064293) Study Title: "Efficacy and Safety of CagriSema in Adults With Overweight or Obesity (REDEFINE 1)" Status: Completed (Results Published 2024) Phase: Phase 3 Enrollment: 3,400+ participants Study Period: 2021-2024 Location: Global, 15+ countries Design: Randomized, double-blind, active-controlled Duration: 68 weeks Intervention: CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) vs
Packaging: Sterile sealed vial
To reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight
US$ 27.42
US$ 21.98
US$ 27.79
US$ 25.93
US$ 23.88
US$ 29.58
US$ 22.80
